STRASBOURG, FRANCE, AND MIDDLETOWN, CT, USA: Qaelon Medical, a pioneer in real-time surgical leak detection and insufflation, and RevMedica, an innovator in surgical stapling solutions, are excited to announce a non-exclusive data partnership to improve stapler performance and clinical outcomes in gastrointestinal surgery.
Partnership Objectives: By integrating RevMedica’s advanced stapler technology with Qaelon’s real-time leak detection and performance data, the collaboration aims to:
Thomas Wenchell, Chief Executive Officer, RevMedica: “Qaelon’s leak detection technology offers RevMedica objective insights to enhance the development of our tissue sensing technology and ultimately improve clinical outcomes. We’re excited about the potential this partnership brings to establish new performance benchmarks while supporting our mission to optimize decision-making in surgery.
Liam Burns, Chief Executive Officer, Qaelon Medical: “Our mission at Qaelon Medical is to address the devastating impact of surgical leaks. By joining forces with RevMedica, we have an opportunity to expand the impact of our life-saving technology while building on the surgical intelligence platform we recently announced with Caresyntax.
Advancing Surgical Stapling with Quantifiable Leak Detection Data: RevMedica’s new Endo Stapling Platform provides digital precision and real-time feedback for minimally invasive procedures by optimizing staple formation and tissue management. Qaelon Medical’s unique solution provides real-time, quantifiable leak detection data that empowers surgeons to take immediate corrective action before the patient leaves the operating room. Both RevMedica and Qaelon Medical technologies have been selected for the FDA’s Safer Technologies Program (STeP), reserved for “medical devices that are reasonably expected to significantly improve the safety of currently available treatments.”
About Qaelon Medical:
Qaelon Medical is pioneering the first and only platform that combines real-time detection of life-threatening surgical leaks with state-of-the-art constant flow surgical insufflation. The company’s breakthrough solution empowers surgical teams with definitive leak test results during surgery, enabling immediate corrective action before the patient leaves the operating room. Qaelon’s platform provides unique objective performance indicators capable of powering AI models on surgical leaks, enhancing the ability to predict, prevent, and address complications before they arise. These advancements not only improve patient outcomes but also reduce the estimated $1.1 billion spent annually in the U.S. to treat surgical leaks. Qaelon’s system enhances traditional insufflation technology with proprietary controls, digital sensors, software, and data algorithms.
Press Contact: yee.ying-douchamps@qaelonmedical.com
About RevMedica:
RevMedica is a pioneering medical technology company revolutionizing the way surgeons approach soft tissue management. The company’s mission focuses on optimizing clinical decision-making and elevating patient safety through the development of cost-effective, environmentally sustainable surgical systems. RevMedica is dedicated to delivering enabling technology that achieves superior clinical results and fosters a more sustainable healthcare ecosystem. Press Contact: tom@revmedica.com Qaelon Medical’s platform and RevMedica’s products are currently under development, have not been cleared by the FDA, and are not yet available for commercial sale in the United States.
